Wisconsin is currently home to 1268 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
NCT02675959
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
05/20/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Sickle Cell Disease
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Aurora St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
NCT06681935
Recruiting
The study design is an observational cohort study of patients undergoing standard of care oral cavity reconstruction. An observational study is required to prospectively evaluate microbial and antibiotic mechanisms underlying surgical site infection after oral cavity reconstruction.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/16/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Oral Cancer
Register for Updates
PDA for Kidneys Study
NCT06658496
Recruiting
The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney injury. Researchers will do this by looking at ultrasound images of the heart, analyzing substances in the urine, and evaluating oxygen levels in the kidneys.
Gender:
ALL
Ages:
Between 1 minute and 7 days
Trial Updated:
05/16/2025
Locations: Meriter Hospital, Inc., Madison, Wisconsin
Conditions: Patent Ductus Arteriosus, Congenital Heart Disease
Register for Updates
Exercise Training in Children With Communication Impairments
NCT06340893
Recruiting
This clinical trial study has two goals. The first goal is to establish fitness levels, participation in physical activities, and fine/gross motor abilities for children with development language disorder (DLD). DLD occurs in 1/13 children and children with DLD often have poorer fine/gross motor skills than those with typical development. The second goal is to determine whether physical exercise helps children with DLD and typical development to learn better and improve fitness and fine/gross mo... Read More
Gender:
ALL
Ages:
Between 5 years and 9 years
Trial Updated:
05/16/2025
Locations: Marquette U, Milwaukee, Wisconsin
Conditions: Developmental Language Disorder
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Parkinson's Disease
Register for Updates
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956
Recruiting
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112
Recruiting
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Endometrial Cancer
Register for Updates
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Duluth Clinic Ashland, Ashland, Wisconsin
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
Register for Updates